Physician Style Crucial in Enrolling Black Men in Clinical Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

WASHINGTON-Despite the high rate of cancer among black men in the United States, their participation in clinical trials is low. The interaction between these patients and their physicians affects willingness to enroll in trials, Dawn L. Riddle, PhD, of the H. Lee Moffitt Cancer Center, reported at the 8th Biennial Symposium on Minorities, the Medically Underserved, and Cancer. She described pilot data indicating that when physicians go beyond simply imparting legal and medical information about the trial and make a strategic effort to answer the patient’s concerns, discover any barriers that impede his participation, and remove those barriers, black men are more likely to consent to participate.

WASHINGTON—Despite the high rate of cancer among black men in the UnitedStates, their participation in clinical trials is low. The interaction betweenthese patients and their physicians affects willingness to enroll in trials,Dawn L. Riddle, PhD, of the H. Lee Moffitt Cancer Center, reported at the 8thBiennial Symposium on Minorities, the Medically Underserved, and Cancer. Shedescribed pilot data indicating that when physicians go beyond simply impartinglegal and medical information about the trial and make a strategic effort toanswer the patient’s concerns, discover any barriers that impede hisparticipation, and remove those barriers, black men are more likely to consentto participate.

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
2 experts are featured in this series.
2 experts are featured in this series.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Related Content